AlphAIAlphAI — Financial news for AI agents
tradingview.com$AGEN

Agenus Reports $31.5 Million Q3 Revenue and $11.4 Million Operating Income

Agenus reported Q3 2026 revenue of $31.5M, operating income of $11.4M, and net income of $2.8M. The company had $86.9M in cash and equivalents. Agenus is preparing its Phase 3 ROBBIN trial and received first marketing authorizations for BOT+BAL in Armenia.

Original reporting
tradingview.com
Published Nov 5, 2026, 1:03 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 1:09 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Agenus Reports $31.5 Million Q3 Revenue and $11.4 Million Operating Income — source image
Source · tradingview.com
Decision brief

The 30-second read

$AGENBullishMed
01

Why it matters

The earnings beat and cash boost could attract short‑term buying, but the company's valuation remains tied to clinical trial outcomes.

02

Market read

Micro‑cap biotech earnings with trial updates; relevant for traders focused on biotech pipelines.

03

What to watch

Potential regulatory delays for the Phase 3 ROBBIN trial and the conditional one‑year authorizations in Armenia.

Relevance 7/10Novelty 7/10Timing: after‑hours release

Background

Agenus Inc. reported its Q3 2026 results, highlighting revenue growth, operating profitability, and cash infusion from a private placement, while advancing a Phase 3 colon cancer trial.

Company-level read

Ticker impact

$AGENBullishMedium confidence
Context

Q3 2026 revenue $31.5M, operating income $11.4M, net income $2.8M disclosed in an 8‑K filing.

Expected impact

likely modest upside as market prices in stronger earnings and cash position

Evidence & confidence

Revenue grew YoY, operating income turned positive for third straight quarter, and a large private placement boosted cash, suggesting improved financial health.

Market effects

Sector

Positive earnings may lift sentiment in the biotech/oncology sector.

Regional

Limited to U.S. biotech investors.

Global

Minimal global impact beyond niche biotech investors.

Counterpoint

What could challenge this read

Despite earnings beat, the small scale and reliance on upcoming Phase 3 trial introduce execution risk.

Key entities

  • company
    Agenus Inc.

    Biotech firm developing immuno‑oncology therapies.

Read at source← All news

Also covered by

2 outlets

Related articles

$AGENMedAI 8/10

Agenus Reports Third Quarter 2026 Results, Highlighted by First Marketing Authorizations for BOT+BAL and Global Investigator Support for Phase 3 ROBBIN Study

AGENUS INC (AGEN) filed an SEC Form 8-K — Results of Operations and Financial Condition. FOR IMMEDIATE RELEASE Agenus Reports Third Quarter 2026 Results, Highlighted by First Marketing Authorizations for BOT+BAL and Global Investigator Support for Phase 3 ROBBIN Study • ROBBIN Phase 3 on track for first patient enrolled in Q1 2027; strong global investigator engageme

SEC EDGAR 8-K
$AGENMedAI 8/10

Agenus advances Phase 3 colon cancer trial, posts Q3 profit

Agenus Inc. (AGEN) reported Q3 revenue of $31.5M, up from $30.2M YoY, with net income of $2.8M. The company announced plans to enroll the first patient in its Phase 3 ROBBIN trial for colon cancer in Q1 2027, with interim results expected in Q4 2027. Two Phase 2 studies showed 30% pathologic complete response rates. Armenia granted marketing authorization for botensilimab and balstilimab. AGEN has $86.9M in cash and raised $85M in a private placement.

investing.com
$AGENMedAI 8/10

Agenus Announces Nature Medicine Publication of Multicenter UNICORN Phase 2 Trial Demonstrating Deep Responses with Neoadjuvant BOT+BAL in Resectable Colon Cancer

Agenus Inc. (AGEN) announced positive results from the Phase 2 UNICORN trial of its cancer treatments, botensilimab (BOT) and balstilimab (BAL), in colon cancer. The trial met its primary endpoint, with a 36% major pathologic response rate in pMMR/MSS colon cancer patients treated with BOT+BAL. No patients in the combination cohorts experienced cancer recurrence, with 12-month event-free survival at 100%. The findings support Agenus' planned Phase 3 ROBBIN trial in MSS/pMMR colon cancer.

simcoereformer.ca